Pamiparib

DB14769InvestigationalSmall molecule

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly...

Mechanism: Pharmacologically active on Poly [ADP-ribose] polymerase 1 and Poly [ADP-ribose] polymerase 2
Curator reviewed
Formula / weight: C₁₆H₁₅FN₄O · 298.321 g/mol (avg)
Code names: BGB-290

Resolves to

Compound

UNII8375F9S90CCAS1446261-44-4ChEMBLCHEMBL4112930

Clinical / RWD

ATCL01XK06

Structure

InChIKeyDENYZIUJOTUUNY-MRXNPFEDSA-NSMILESC[C@]12CCCN1CC1=NNC(=O)C3=C4C(NC2=C14)=CC(F)=C3

Targets

P09874PARP1Q9UGN5PARP2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

35Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 5 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pamiparib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In